Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease

Kidney International

Volumn 82, Issue 1, 2012, Pages 19-25

  Torres, Pablo A Ureña ^a   De Broe, Marc ^b  

^a Clinique du Landy   (France)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

calcimimetics; calcium receptor; hyperparathyroidism; parathyroid hormone; renal osteodystrophy; vascular calcification

Indexed keywords

AR 265347; CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CALINDOL; CINACALCET; NPS R 567; NPS S 567; NPS S 568; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; PHOSPHATE; TECALCET; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; EXTRACELLULAR CALCIUM; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MINERALIZATION; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 84862498822     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.69     Document Type: Review

References (69)

1. Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
2. Nakamura S, Ishibashi-Ueda H, Niizuma S et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 2009; 4: 1892-1900.
3. Hutchison AJ, Whitehouse RW, Freemont AJ et al. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 1994; 14: 19-29. (Pubitemid 24121288)
4. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401. (Pubitemid 26075849)
5. Kramer H, Toto R, Peshock R et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513. (Pubitemid 41725148)
6. Ejerblad S, Ericsson JL, Eriksson I. Arterial lesions of the radial artery in uraemic patients. Acta Chirurgica Scandinavica 1979; 145: 415-428. (Pubitemid 10160965)
7. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964. (Pubitemid 39578826)
8. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021. (Pubitemid 30410374)
9. Nakano T, Ninomiya T, Sumiyoshi S et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama Study. Am J Kidney Dis 2010; 55: 21-30.
10. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483. (Pubitemid 30318271)
11. London GM, Marchais SJ, Metivier F et al. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant 2000; 15(Suppl 5): 97-104.
12. Raggi P, Giachelli C, Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007; 4: 26-33. (Pubitemid 44971069)
13. US V. Patient mortality and survival in ESRD. Am J Kidney Dis 1999; 34: S74-S86.
14. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
15. London GM, Pannier B, Marchais SJ et al. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000; 11: 778-783. (Pubitemid 30171888)
16. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580. (Pubitemid 24035999)
17. Smajilovic S, Hansen JL, Christoffersen TE et al. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 2006; 348: 1215-1223. (Pubitemid 44308418)
18. Ziegelstein RC, Xiong Y, He C et al. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 2006; 342: 153-163. (Pubitemid 43247372)
19. Urena P, Frazao JM. Calcimimetic agents: review and perspectives. Kidney Int Suppl 2003; 63: S91-S96. (Pubitemid 36605872)
20. Ma JN, Owens M, Gustafsson M et al. Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther 2011; 337: 275-284.
21. Henley III C, Yang Y, Davis J et al. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. J Pharmacol Exp Ther 2011; 337: 681-691.
22. Alam MU, Kirton JP, Wilkinson FL et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81: 260-268.
23. Alam R, Kataoka S, Alam S et al. Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: role of protein kinase C. Atherosclerosis 1996; 126: 207-219. (Pubitemid 26336657)
24. Molostvov G, James S, Fletcher S et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007; 293: F946-F955. (Pubitemid 47403367)
25. Fryer RM, Segreti JA, Widomski DL et al. Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet. J Pharmacol Exp Ther 2007; 323: 217-226. (Pubitemid 47443245)
26. Odenwald T, Nakagawa K, Hadtstein C et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006; 17: 655-662.
27. Ogata H, Ritz E, Odoni G et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959-967. (Pubitemid 36359277)
28. Koleganova N, Piecha G, Ritz E et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009; 75: 60-71.
29. -/-) mice. Atherosclerosis 2009; 205: 55-62.
30. Lopez I, Mendoza FJ, Guerrero F et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009; 296: F1376-F1385.
31. Henley C, Davis J, Miller G et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313.
32. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
33. Kawata T, Nagano N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270-1277.
34. Urena P, Kong XF, Abou-Samra AB et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 1993; 133: 617-623. (Pubitemid 23238871)
35. Bechara A, Helwig JJ, Bollack C. Action of parathyroid hormone on the secretion of renin and arterial pressure in the rabbit. Arch Esp Urol 1988; 41: 255-263.
36. Fritsch S, Lindner V, Welsch S et al. Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 2004; 15: 2588-2600. (Pubitemid 41103365)
37. Heyliger A, Tangpricha V, Weber C et al. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery 2009; 146: 1042-1047.
38. Smith JC, Page MD, John R et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3515-3519.
39. Shao JS, Cheng SL, Charlton-Kachigian N et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195-50202. (Pubitemid 37548859)
40. Hosoi M, Nishizawa Y, Morii H. PTH, PTHrP, and CGRP in hypertension research. Nippon Rinsho 1997; 55: 1950-1957.
41. Huang Z, Li J, Jiang Z et al. Effects of adrenomedullin, C-type natriuretic peptide, and parathyroid hormone-related peptide on calcification in cultured rat vascular smooth muscle cells. J Cardiovasc Pharmacol 2003; 42: 89-97. (Pubitemid 36791355)
42. Mori K, Shioi A, Jono S et al. Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 1998; 433: 19-22. (Pubitemid 28386723)
43. Okano K, Wu S, Huang X et al. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor and its messenger ribonucleic acid in rat aortic vascular smooth muscle cells and UMR osteoblast-like cells: cell-specific regulation by angiotensin-II and PTHrP. Endocrinology 1994; 135: 1093-1099.
44. Whitfield JF. Osteogenic PTHs and vascular ossification-is there a danger for osteoporotics? J Cell Biochem 2005; 95: 437-444. (Pubitemid 41420174)
45. Urena P, Ferreira A, Morieux C et al. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 1996; 11: 2008-2016. (Pubitemid 26345466)
46. Brossard JH, Yamamoto LN, D'Amour P. Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Semin Dial 2002; 15: 196-201. (Pubitemid 41765931)
47. Gonzalez E, Martin K. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 1996; 50: 63-70. (Pubitemid 26323698)
48. Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270. (Pubitemid 46884255)
49. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
50. London GM, Marchais SJ, Guerin AP et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531. (Pubitemid 41531842)
51. Elder G, Kumar KS. Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH- (1-34). Nephrol Dial Transplant 2008; 2: 97-99. (Pubitemid 351486418)
52. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114. (Pubitemid 41033466)
53. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007; 71: 282-283. (Pubitemid 46227084)
54. Proudfoot D, Shanahan CM. Nanocrystals seed calcification in more ways than one. Kidney Int 2011; 79: 379-382.
55. Schlieper G, Aretz A, Verberckmoes SC et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21: 689-696.
56. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
57. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824. (Pubitemid 43169927)
58. Meema HE, Oreopoulos DG, deVeber GA. Arterial calcifications in severe chronic renal disease and their relationship to dialysis treatment, renal transplant, and parathyroidectomy. Radiology 1976; 121: 315-321.
59. Girotto JA, Harmon JW, Ratner LE et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 2001; 130: 645-650; discussion 650-641.
60. Di Leo C, Gallieni M, Bestetti A et al. Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy. Clin Nephrol 2003; 59: 59-63. (Pubitemid 36150467)
61. Bleyer AJ, Burkart J, Piazza M et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46: 464-469. (Pubitemid 41208182)
62. Velasco N, MacGregor MS, Innes A et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21: 1999-2004. (Pubitemid 43985736)
63. Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol 2006; 155: 1295-1297. (Pubitemid 44730012)
64. Mohammed IA, Sekar V, Bubtana AJ et al. Proximal calciphylaxis treated with calcimimetic 'cinacalcet'. Nephrol Dial Transplant 2008; 23: 387-389. (Pubitemid 351767416)
65. Floege J, Raggi P, Block GA et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1916-1923.
66. Raggi P, Chertow GM, Torres PU et al. The ADVANCE Study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
67. Raggi P, Bellasi A, Gamboa C et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol 2011; 6: 1990-1995.
68. Urena P, Malergue MC, Goldfarb B et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999; 20: 217-225. (Pubitemid 29398188)
69. Chertow GM, Pupim LB, Block GA et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905.